Corrigendum to original article
Nargenicin A1 attenuates lipopolysaccharide-induced inflammatory and oxidative response by blocking the NF-κB signaling pathway
EXCLI Journal 2021;20:968-982
Correction of duplicated figures in http://dx.doi.org/10.17179/excli2021-3506
In the article "Nargenicin A1 attenuates lipopolysaccharide-induced inflammatory and oxida-tive response by blocking the NF-κB signaling pathway" published in EXCLI Journal (EXCLI J. 2021 May 28;20:968-982. doi: 10.17179/excli2021-3506), a duplication error was identified in Figures 1 and 2. Both figures, though described differently in their figure legends, were found to be identical. Figure 1 should be: (Fig. 1)
Figure 2 is correct.
Editorial Office/EXCLI Journal on behalf of the corresponding author
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
http://creativecommons.org/licenses/by/4.0/.
[*] Corresponding Author:
Yung Hyun Choi, Department of Biochemistry, Dong-eui University College of Korean Medicine, 52-57, Yangjeong-ro, Busan 47227, Republic of Korea; Tel: 82-51-890-3319, Fax: +82-51-890-3333, eMail: choiyh@deu.ac.kr
Figure 1: Effect of nargenicin A1 and LPS on the cell viability of RAW 264.7 macrophages. Cells were treated with various concentrations of nargenicin A1 alone for 24 h or pre-treated with or without nargenicin A1 for 1 h before 100 ng/ml LPS stimulation for 24 h. Cell viability was analyzed using the MTT assay. H2O2 was used as a positive control. Each value indicates the mean ± SD and is representative of three independent experiments. Significant differences among the groups were determined (***p < 0.001, vs. LPS-unstimulated cells).